Screener
Design Therapeutics, Inc. DSGN EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development (including related party amounts of $72 and $228, respectively) | $14,379 | $15,377 |
| General and administrative (including related party amounts of $85 and $134, respectively) | 5,327 | 5,041 |
| Total operating expenses | 19,706 | 20,418 |
| Loss from operations | (19,706) | (20,418) |
| Interest income | 2,070 | 2,703 |
| Net loss | $(17,636) | $(17,715) |
| Net loss per share, basic and diluted | $(0.29) | $(0.31) |
| Weighted-average shares of common stock outstanding, basic and diluted | 61,434,457 | 56,757,827 |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s EPS (diluted)?
- Design Therapeutics, Inc. (DSGN) reported EPS (diluted) of -$0.29 in Q1 2026.
- How has Design Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Design Therapeutics, Inc.'s EPS (diluted) increased by 6.5% year-over-year, from -$0.31 to -$0.29.
- What is the long-term trend for Design Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s EPS (diluted) has grown at a 9.1% compound annual growth rate (CAGR), from -$0.86 to -$1.22.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Design Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude